Sunesis Pharmaceuticals, Inc. Reports Third Quarter 2012 Financial Results and Recent Highlights

Published: Nov 08, 2012

SOUTH SAN FRANCISCO, Calif., Nov. 8, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today reported financial results for the quarter ended September 30, 2012. Net loss for the three and nine months ended September 30, 2012 was $17.4 million and $39.9 million, respectively, including non-cash charges of $8.1 million and $12.3 million, respectively, related to the valuation of warrants. As of September 30, 2012, cash, cash equivalents and marketable securities totaled $76.6 million. Subsequent to the quarter end, Sunesis raised $3.6 million through a combination of common stock sales and warrant exercises, bringing pro-forma cash, cash equivalents and marketable securities as of September 30, 2012 to $80.2 million.

Back to news